The PI3K/mTOR Inhibitor Gedatolisib Eliminates Dormant Breast Cancer Cells in Organotypic Culture, but Fails to Prevent Metastasis in Preclinical Settings

By probing a number of kinases downstream of integrin-β1, scientists determined that PI3K inhibition with either a tool compounds or a compound in clinical trials robustly sensitizes quiescent breast tumor cells seeded in organotypic bone marrow cultures to chemotherapy.